STORM Therapeutics and Alida Bio Unite to Enhance Development of Cancer Treatments through RNA Modifications STORM Therapeutics and Alida Bio have announced a collaboration aimed at advancing cancer therapies by focusing on RNA modifications, leveraging advanced sequencing technologies for groundbreaking treatment insights.

STORM Therapeutics and Alida Bio Unite to Enhance Development of Cancer Treatments through RNA Modifications #Cambridge #United_Kingdom #STORM_Therapeutics #AlidaBio #RNA_modifications

STORM Therapeutics Appoints Dr. Eric Martin as Chief Development Officer to Lead Innovative Cancer Drug Development STORM Therapeutics appointed Dr. Eric Martin as Chief Development Officer, signaling a strong commitment to developing next-gen cancer therapies through RNA modifications.

STORM Therapeutics Appoints Dr. Eric Martin as Chief Development Officer to Lead Innovative Cancer Drug Development #Cambridge #United_Kingdom #STORM_Therapeutics #STC-15 #Dr._Eric_Martin

STORM Therapeutics Begins Patient Dosing in Collaboration Using STC-15 with LOQTORZI and Welcomes New CMO STORM Therapeutics has initiated patient dosing in a study combining STC-15 with LOQTORZI. Atif Abbas, M.D., has been appointed CMO to drive this effort.

STORM Therapeutics Begins Patient Dosing in Collaboration Using STC-15 with LOQTORZI and Welcomes New CMO #Cambridge #United_Kingdom #STORM_Therapeutics #STC-15 #LOQTORZI